Compare GCV & BHST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GCV | BHST |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | Canada |
| Employees | N/A | 87 |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.0M | 97.7M |
| IPO Year | 1994 | N/A |
| Metric | GCV | BHST |
|---|---|---|
| Price | $4.43 | $4.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 41.4K | 26.8K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $146.27 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.32 | $4.10 |
| 52 Week High | $4.56 | $12.80 |
| Indicator | GCV | BHST |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 45.93 |
| Support Level | $4.14 | $4.27 |
| Resistance Level | $4.54 | $5.02 |
| Average True Range (ATR) | 0.12 | 0.14 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 66.67 | 20.83 |
GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive, and others. All the operation of the group is operated through the regions of the United States.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.